ASX Announcements Due to legal restrictions, only residents of Australia and New Zealand may access ASX announcements that contain information or materials relating to any capital raising. Keyword Search Year None20202019 Date Title 07 July 2020 Appendix 3B, 2A with prospectus- Kentgrove Capital 06 July 2020 EAP for Remestemcel-L in Children with MIS-C due to COVID-19 30 June 2020 Appendix 2A 24 June 2020 Appendix 3G with 3Ys 16 June 2020 Appendix 2A 12 June 2020 S&P DJI Announces June 2020 Quarterly Rebalance 01 June 2020 Appendix 2A 01 June 2020 Remestemcel-L Improves Outcomes in Inflammatory Lung Disease 28 May 2020 MSB Reports Q3 Financial Results and Operational Highlights 28 May 2020 Third Quarter Results Presentation 28 May 2020 Third Quarter Financial Results on Form 6-K 27 May 2020 Change in substantial holding 25 May 2020 3 Articles on RYONCIL GvHD Trial Results Published in BBMT 19 May 2020 Change in substantial holding 18 May 2020 Cleansing Notice 15 May 2020 Appendix 2As 13 May 2020 Proposed issue of Securities - MSB 13 May 2020 MSB Completes Financing For Covid-19 ARDS Manufacturing 11 May 2020 Trading Halt 06 May 2020 First Patients Dosed in Phase 2/3 Trial for COVID-19 ARDS 30 April 2020 Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment 29 April 2020 Appendix 4C - quarterly 24 April 2020 83% Survival in COVID-19 ARDS Patients with Remestemcel-L 17 April 2020 Inflammatory Lung Disease Outcomes For Presentation at ISCT 09 April 2020 US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial 06 April 2020 FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients 01 April 2020 FDA Accepts BLA for RYONCIL and Agrees to Priority Review 30 March 2020 Ischemic End Stage HF Outcomes at Virtual ACC Annual Meeting 20 March 2020 Change of Director's Interest Notice 17 March 2020 Appendix 2A 10 March 2020 Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease 27 February 2020 Mesoblast Provides Half Year Results and Corporate Update 27 February 2020 Half Year Financial Results Presentation 27 February 2020 Half Year Report and Accounts (including Appendix 4D) 25 February 2020 Mesoblast Half Year FY 2020 Financial Results Analyst Call 24 February 2020 Ryoncil Results in Children with Acute GvHD Presented at TCT 21 February 2020 Appendix 3G 20 February 2020 Positive Outcomes Using Remestemcel-L in Chronic GVHD 07 February 2020 Appendix 2A 03 February 2020 Mesoblast Submits Completed BLA for Ryoncil to US FDA 29 January 2020 Appendix 4C - quarterly 24 January 2020 Appendix 2A 15 January 2020 Biotech Showcase Presentation 15 January 2020 MSB Presents Commercial Plans at 2020 Biotech Showcase 02 January 2020 Appendix 2A 02 January 2020 MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
